Anastrozole and Goserelin (a gonadotropin-releasing hormone) Combo, May Slow Male Breast Cancer
Male breast cancer is a rare disease usually undiagnosed until it’s in an advanced stage. Now, medical oncologists across the United States are seeking to know whether a certain drug combination can slow the progression of male breast cancer.
The drug anastrozole (Arimidex) is currently approved by the USFDA for treating breast cancer in postmenopausal women, known as non-steroidal aromatase inhibitors that block the tumor’s use of estrogen and slow its development.
By combining anastrozole and a synthetic hormone called goserelin, the research team (headed by Zeina Nahleh, MD, director of breast oncology in the University of Cincinnati’s (UC) division of hematology and oncology) believes that physicians may be able to stop the transition of the male hormone testosterone to the estrogen estradiol thereby significantly lowering the man’s overall estrogen levels and limiting breast tumor growth.
“The biology of breast cancer is different in men and women, so identical treatment methods are not the best solution,” explains Nahleh. “We believe that anastrozole—when used in conjunction with a gonadotropin-releasing hormone injection—will lower the amount of male estrogen in the body, resulting in better control of the breast tumor.”
This nationwide trial that is first to test this specific drug combination in men with advanced breast cancer is sponsored by the National Cancer Institute and Southwest Oncology Group.
Read more at UC Health News.
Related Stories
POSTED IN: on breast cancer
0 opinions for Anastrozole and Goserelin (a gonadotropin-releasing hormone) Combo, May Slow Male Breast Cancer
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: